Noninfectious, Severe Cryoglobulinemic Vasculitis with Renal Involvement – Safety and Efficacy of Long-Term Treatment with Rituximab

BACKGROUND: The management of nonviral cryoglobulinemic vasculitis (CV) has not been established yet. Randomized control trials are challenging to perform because of the rarity of the disease. The most promising biological therapy is rituximab (RTX), an anti-CD 20 monoclonal antibody. The aim of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Leśniak, Ksymena, Rymarz, Aleksandra, Lubas, Arkadiusz, Niemczyk, Stanisław
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8291846/
https://www.ncbi.nlm.nih.gov/pubmed/34295176
http://dx.doi.org/10.2147/IJNRD.S315388

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8291846/
https://www.ncbi.nlm.nih.gov/pubmed/34295176
http://dx.doi.org/10.2147/IJNRD.S315388

Ejemplares similares